HomeCompareESALY vs KMB

ESALY vs KMB: Dividend Comparison 2026

ESALY yields 31.26% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ESALY wins by $252.8K in total portfolio value
10 years
ESALY
ESALY
● Live price
31.26%
Share price
$61.51
Annual div
$19.23
5Y div CAGR
7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$298.7K
Annual income
$71,135.45
Full ESALY calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — ESALY vs KMB

📍 ESALY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodESALYKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ESALY + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ESALY pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ESALY
Annual income on $10K today (after 15% tax)
$2,657.23/yr
After 10yr DRIP, annual income (after tax)
$60,465.13/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, ESALY beats the other by $56,026.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ESALY + KMB for your $10,000?

ESALY: 50%KMB: 50%
100% KMB50/50100% ESALY
Portfolio after 10yr
$172.3K
Annual income
$38,178.89/yr
Blended yield
22.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

ESALY
No analyst data
Altman Z
5.1
Piotroski
4/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ESALY buys
0
KMB buys
0
No recent congressional trades found for ESALY or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricESALYKMB
Forward yield31.26%5.25%
Annual dividend / share$19.23$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR7%17%
Portfolio after 10y$298.7K$45.9K
Annual income after 10y$71,135.45$5,222.34
Total dividends collected$238.7K$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ESALY vs KMB ($10,000, DRIP)

YearESALY PortfolioESALY Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$14,045$3,344.99$11,314$614.45+$2.7KESALY
2$19,726$4,698.03$12,867$760.19+$6.9KESALY
3$27,705$6,598.37$14,713$945.27+$13.0KESALY
4$38,912$9,267.41$16,924$1,181.90+$22.0KESALY
5$54,652$13,016.06$19,596$1,486.64+$35.1KESALY
6$76,759$18,281.04$22,850$1,882.16+$53.9KESALY
7$107,808$25,675.69$26,849$2,399.80+$81.0KESALY
8$151,416$36,061.47$31,812$3,083.36+$119.6KESALY
9$212,663$50,648.29$38,033$3,994.72+$174.6KESALY
10$298,685$71,135.45$45,918$5,222.34+$252.8KESALY

ESALY vs KMB: Complete Analysis 2026

ESALYStock

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Full ESALY Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this ESALY vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ESALY vs SCHDESALY vs JEPIESALY vs OESALY vs KOESALY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.